Donald L. Durden

6.5k total citations
108 papers, 5.3k citations indexed

About

Donald L. Durden is a scholar working on Molecular Biology, Immunology and Hematology. According to data from OpenAlex, Donald L. Durden has authored 108 papers receiving a total of 5.3k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Molecular Biology, 21 papers in Immunology and 15 papers in Hematology. Recurrent topics in Donald L. Durden's work include PI3K/AKT/mTOR signaling in cancer (22 papers), Protein Degradation and Inhibitors (18 papers) and Monoclonal and Polyclonal Antibodies Research (14 papers). Donald L. Durden is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (22 papers), Protein Degradation and Inhibitors (18 papers) and Monoclonal and Polyclonal Antibodies Research (14 papers). Donald L. Durden collaborates with scholars based in United States, South Korea and Canada. Donald L. Durden's co-authors include Shweta Joshi, Daniel J. Brat, Erwin G. Van Meir, Yuan Rong, Alok R. Singh, Jing Su, Pradip De, David B. Donner, Lindsey D. Mayo and Joseph R. Garlich and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Donald L. Durden

104 papers receiving 5.2k citations

Peers

Countries citing papers authored by Donald L. Durden

Since Specialization

Citations

This map shows the geographic impact of Donald L. Durden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald L. Durden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald L. Durden more than expected).

Fields of papers citing papers by Donald L. Durden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald L. Durden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald L. Durden. The network helps show where Donald L. Durden may publish in the future.

Co-authorship network of co-authors of Donald L. Durden

This figure shows the co-authorship network connecting the top 25 collaborators of Donald L. Durden. A scholar is included among the top collaborators of Donald L. Durden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald L. Durden. Donald L. Durden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery of a “First-in-Class” Selective Multikinase (CDK4/6/9-AURKA/B) Inhibitor, LCI133, for Neuroblastoma 2025 ·Journal of Medicinal Chemistry ·Maddeboina Krishnaiah, (unknown), (unknown), (unknown), Sandeep Kumar Singh, Yashpal S. Chhonker, (unknown), (unknown), (unknown), (unknown), Daryl J. Murry, Donald L. Durden	0
2	Recent advances in multitarget-directed ligands via in silico drug discovery 2024 ·Drug Discovery Today ·Maddeboina Krishnaiah, (unknown), Shikha Kumari, (unknown), (unknown), Donald L. Durden	10
3	The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma 2021 ·iScience ·(unknown), Kendra R. Vann, Shweta Joshi, Namood-e Sahar, Guillermo Morales, Dalia El‐Gamal, Tatiana G. Kutateladze, Donald L. Durden	8
4	A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity 2020 ·Cell Discovery ·Adam M. Burgoyne, Kendra R. Vann, Shweta Joshi, Guillermo Morales, Francisco M. De La Vega, Alok Singh, (unknown), (unknown), Tatiana G. Kutateladze, Donald L. Durden	13
5	Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma 2020 ·Cancers ·Venugopal Gunda, Anup S. Pathania, Srinivas Chava, Philip Prathipati, Nagendra K. Chaturvedi, Donald W. Coulter, Manoj K. Pandey, Donald L. Durden, Kishore B. Challagundla	18
6	SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer 2019 ·Molecular Cancer Therapeutics ·Shweta Joshi, Alok R. Singh, Kevin X. Liu, Timothy V. Pham, Muamera Zulcic, Dylan Skola, Hyun Bae Chun, Christopher K. Glass, Guillermo Morales, Joseph R. Garlich, Donald L. Durden	41
7	Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis 2017 ·Proceedings of the National Academy of Sciences ·Forest H. Andrews, Alok R. Singh, Shweta Joshi, Cassandra Smith, Guillermo A. Morales, Joseph R. Garlich, Donald L. Durden, Tatiana G. Kutateladze	98
8	Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma 2016 ·Molecular Cancer Therapeutics ·Alok R. Singh, Shweta Joshi, Adam M. Burgoyne, Jason K. Sicklick, Sadakatsu Ikeda, Yuko Kono, Joseph R. Garlich, Guillermo A. Morales, Donald L. Durden	51
9	Rac2 Controls Tumor Growth, Metastasis and M1-M2 Macrophage Differentiation In Vivo 2014 ·PLoS ONE ·Shweta Joshi, Alok R. Singh, Muamera Zulcic, Lei Bao, Karen Messer, Trey Ideker, Janusz Dutkowski, Donald L. Durden	104
10	Epidermal Growth Factor Receptor and PTEN Modulate Tissue Factor Expression in Glioblastoma through JunD/Activator Protein-1 Transcriptional Activity 2009 ·Cancer Research ·Yuan Rong, Vladimir E. Belozerov, Carol Tucker‐Burden, (unknown), Donald L. Durden, Jeffrey J. Olson, Erwin G. Van Meir, Nigel Mackman, Daniel J. Brat	114
11	In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells 2009 ·Cancer Chemotherapy and Pharmacology ·Tuba Ozbay, Donald L. Durden, Tongrui Liu, Ruth O’Regan, Rita Nahta	36
12	Regulation of XIAP Translation and Induction by MDM2 following Irradiation 2009 ·Cancer Cell ·Lubing Gu, Ningxi Zhu, Hongying Zhang, Donald L. Durden, Yue Feng, Muxiang Zhou	140
13	A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity 2008 ·Cancer Research ·Joseph R. Garlich, Pradip De, Nandini Dey, Jing Su, Xiaodong Peng, (unknown), (unknown), Yiling Lu, Gordon B. Mills, Vikas Kundra, (unknown), Qiong Peng, Donald L. Durden	230
14	Preclinical studies of a pan PI3K inhibitor (SF1126) in renal cell carcinoma 2007 ·Cancer Research ·Qiong Peng, Pradip De, Nandini Dey, Joseph R. Garlich, Donald L. Durden	1
15	Rap1a Null Mice Have Altered Myeloid Cell Functions Suggesting Distinct Roles for the Closely Related Rap1a and 1b Proteins 2007 ·The Journal of Immunology ·Yu Li, (unknown), Pradip De, Hua-Chen Chang, Akira Yamauchi, Kent W. Christopherson, (unknown), Xiaodong Peng, Chaekyun Kim, (unknown), Reuben Kapur, Hanying Chen, Weinian Shou, James C. Stone, Mark H. Kaplan, Mary C. Dinauer, Donald L. Durden, Lawrence A. Quilliam	92
16	CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity 2005 ·Experimental Cell Research ·Nandini Dey, Brian W. Howell, Pradip De, Donald L. Durden	31
17	Ceramide Signaling in Fenretinide-induced Endothelial Cell Apoptosis 2002 ·Journal of Biological Chemistry ·Anat Erdreich‐Epstein, Linda Tran, (unknown), Hongtao Wang, Myles C. Cabot, Donald L. Durden, (unknown), C. Patrick Reynolds, Monique F. Stins, Susan Groshen, Melissa Millard	72
18	High Affinity IgG Receptor Activation of Src Family Kinases Is Required for Modulation of the Shc-Grb2-Sos Complex and the Downstream Activation of the Nicotinamide Adenine Dinucleotide Phosphate (Reduced) Oxidase 1999 ·The Journal of Immunology ·Raekil Park, Anat Erdreich‐Epstein, Ming Liu, (unknown), Donald L. Durden	9
19	Characterization of Cbl-Nck and Nck-Pak1 Interactions in Myeloid FcγRII Signaling 1998 ·Experimental Cell Research ·(unknown), Anat Erdreich‐Epstein, (unknown), Donald L. Durden	25
20	Functions of the major tyrosine phosphorylation site of the PDGF receptor beta subunit. 1991 ·PubMed ·Andrius Kazlauskas, Donald L. Durden, Jonathan A. Cooper	85

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact